Nasdaq22d
Pharvaris Reports Sustained Reduction in HAE Attack Rates and Improved Quality of Life Across Long-Term Deucrictibant Studies
The reduced monthly HAE attack rate was maintained for at least ... and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of deucrictibant ...
KELOLAND News22d
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Reduced monthly HAE attack rate maintained for at least ... and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of deucrictibant, which is ...